Hypercaloric, hyperproteic oral supplement
Hypercaloric, hyperproteic oral supplement has been studied in 1 paper since 2023: 1 trial in people. The newest paper, Dec 28, 2023: “Mediterranean Diet, Vitamin D, and Hypercaloric, Hyperproteic Oral Supplements for Treating Sarcopenia in Patients with Heart Failure-A Randomized Clinical Trial”.
1 paper studies it4 findingsUpdated
See all 1 papers on hypercaloric, hyperproteic oral supplement
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“lean mass, and body mass increased in the intervention group (absolute increase of 0.5, p = 0.03, 1.2 kg, p = 0.03, and 0.1 kg, p = 0.03 respectively)”
None of its findings points the other way.
- 1 lab in 1 country
- Funder: Instituto de Salud Carlos III
- Human trial1
Studies in people
1 study gave hypercaloric, hyperproteic oral supplement to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases muscle mass55.3 kg (50.1–61.1) at the end of the study vs. 52.5 kg (49.8–60.9) at baseline down: Decreases NT-proBNPdecreased by 1303 pg/mL (741–2111) after 24 weeks | Randomized trialtwenty-four weeks | 38 peopleMost of them were male (71.1%)median age of 67.5 y-oldPatients with heart failure and LVEF < 50% | Nutrients, Dec 28, 2023 |
What did studies of hypercaloric, hyperproteic oral supplement find?
2Studies of hypercaloric, hyperproteic oral supplement measured 2 outcomes: NT-proBNP and muscle mass.
NT-proBNP
downin humans1
1 study
NT-proBNP
downin humans1
Hypercaloric, hyperproteic oral supplement decreases NT-proBNP in humans (plus Mediterranean diet) (decreased by 1303 pg/mL (741–2111) after 24 weeks).
“In particular, the intervention group (1952 pg/mL (1179–3307 at baseline) decreased by 1303 pg/mL (741–2111) after 24 weeks (p = 0.02). Although NT-proBNP also decreased in the control group, this change was not statistically significant.”
Human trialplus Mediterranean diettwenty-four weeksn = 19
Nutrients
Hypercaloric, hyperproteic oral supplement decreases NT-proBNP in patients with heart failure.
“Serum values of NT-proBNP also significantly decreased in the whole cohort (p < 0.01), especially in the intervention group (p = 0.02)”
Human trialin patients with heart failure24 weeksn = 38
Nutrients
Muscle mass
upin humans1
1 study
Muscle mass
upin humans1
Hypercaloric, hyperproteic oral supplement increases muscle mass in humans (plus Mediterranean diet) (55.3 kg (50.1–61.1) at the end of the study vs. 52.5 kg (49.8–60.9) at baseline).
“When lean mass was analyzed, it significantly increased in the intervention group (55.3 kg (50.1–61.1) at the end of the study vs. 52.5 kg (49.8–60.9) at baseline, p = 0.03).”
Human trialplus Mediterranean diettwenty-four weeksn = 19
Nutrients
Hypercaloric, hyperproteic oral supplement increases muscle mass in patients with heart failure (+1.2 kg).
“lean mass, and body mass increased in the intervention group (absolute increase of 0.5, p = 0.03, 1.2 kg, p = 0.03, and 0.1 kg, p = 0.03 respectively)”
Human trialin patients with heart failuretwenty-four weeksn = 38
Nutrients